1068 results about "Oral medication" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg / mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

The application belongs to the technical field of animal models for basic scientific research, and particularly relates to a method for establishing an acute lung injury animal model, which comprises the following steps: sending a podophyllotoxin or a podophyllotoxin reagent into a rat body through oral administration or intragastric perfusion to obtain the acute lung injury animal model. The method for establishing the acute lung injury animal model provided by the application uses the podophyllotoxin as an inducer for establishing a mouse acute lung injury model, and the mouse can orally take or intragastrically perfuse the podophyllotoxin to achieve the method, without needing a special medicine injection device, so that the method is simple in medicine taking, few in experimental steps, and does not need complex surgical operations.

Compositions including prebiotics, probiotics, and postbiotics for oral administration and methods of using such compositions for improving health of subjects are provided.

The present invention relates to a pharmaceutical composition for oral administration comprising a GLP receptor agonist or a pharmaceutically acceptable salt or derivative thereof, one or more penetration enhancers, one or more mucous membrane adhesives, and one or more basifying agents. More preferably, the penetration enhancer is a penetration enhancer based on medium chain fatty acids.

The present disclosure provides a caregiver system and method for interfacing with and controlling an oral medication dispensing device. The system registers the caregiver and provides the caregiver a list of patients under the caregiver's care, as well as associated medication dose schedules for each of the one or more patients. The caregiver is provided reminders regarding doses and allowed to modify the dose schedule to generate a modified dose schedule. The modified does schedule is pushed to a patient system associated with a medication dispensing device.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The invention provides a nanocrystalline composite oral ulcer film agent as well as a preparation method and application thereof. The nanocrystalline composite oral ulcer film agent comprises a waterproof backing layer and a drug-loading adhesion layer coated on the waterproof backing layer, the drug-loaded adhesion layer comprises a macromolecular hydrogen bond compound formed by a weakly acidic polymer and a nonionic proton receptor polymer, and a nanocrystalline drug. Compared with the prior art, the preparation method has the advantages that the polyacrylic acid polymer and the nonionic cellulose polymer interact to form IPC serving as an adhesion layer film-forming material, the nanocrystals are loaded into the adhesion layer film-forming material, the waterproof backing layer is coated with the adhesion layer film-forming material, and the oral ulcer film agent is prepared after drying and cutting. The obtained film agent has good comfort and adhesive power, shows good drug stability and permeation promotion performance, can be used as a carrier of an oral administration route, prolongs the drug action time and improves the curative effect. The preparation method of the film agent is simple and easy for industrial mass production.

Provided herein are formulations for oral delivery or administration of therapeutic nucleic acids. An oral formulation can include: a nucleic acid; at least one casein protein; and a chitosan. In some embodiments, the formulations are liposome-free formulations having no cationic lipids typically used as transfection reagents in conventional nucleic acid formulations for oral delivery. The formulations provided herein find use in treating a condition associated with inflammation and / or fibrosis, or a cardiometabolic disorder by oral administration.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of nano-materials, in particular to a monatomic nano-enzyme drug delivery system for IBD treatment and a preparation method and application of the monatomic nano-enzyme drug delivery system. The monatomic nano enzyme delivery system provided by the invention comprises an iron-doped monatomic nano enzyme Fe-SA, curcumin Cur and hyaluronic acid grafted dopamine HAD, the Fe-SA and the Cur form a Fe-SA / Cur compound through a coordination effect, and the surface of the Fe-SA / Cur compound is coated with the HAD. According to the iron-doped monatomic nano-enzyme Fe-SA, Fe atoms in the iron-doped monatomic nano-enzyme Fe-SA are distributed in a graded carbon-based matrix of the Fe-SA in a Fe-N4 co-doping form, and the iron-doped monatomic nano-enzyme Fe-SA has efficient SOD and CAT nano-enzyme activity, and can realize antioxidant self-cascade nano-enzyme reaction, effectively remove active oxygen and improve the pathological environment. According to the preparation method disclosed by the invention, a coordination compound Fe-SA / Cur is constructed by utilizing the iron-doped monatomic nano-enzyme and the curcumin, so that the anti-inflammatory effect is improved, and the characteristic of poor water solubility of the curcumin is effectively improved. According to the invention, HAD is loaded on the outer layer of a coordination compound Fe-SA / Cur to construct an oral monatomic antioxidant cascade nano-enzyme system, high acid resistance and targeted delivery capability are realized by using the remarkable stability and negative charges of HAD, and oral administration is effectively realized. In-vivo and in-vitro experiments show that the monatomic nano-enzyme delivery system provided by the invention can effectively remove intestinal free radicals, improve the intestinal environment, reduce the expression of inflammatory factors, promote the recovery of damaged tissues and effectively treat colitis. The invention provides a new thought and method for biomedical research and drug development of inflammatory bowel diseases.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-lactic acid in preparation of medicines for treating diabetes and complications. A db / db mouse is utilized to simulate the pathological process of human diabetes, the db / db mouse is orally administered with indole-3-lactic acid, and after the db / db mouse orally administered with indole-3-lactic acid, the blood glucose and blood fat of the diabetic mouse can be reduced, the cardiac function impairment of the diabetic mouse is improved, and the brain cognitive dysfunction of the diabetic mouse is improved. It is proved that the indole-3-lactic acid has a treatment effect on diabetes and cardiovascular and cerebrovascular complications thereof.

Use of a bitter melon exosome and an oral medicament prepared therefrom. The bitter melon exosome obtained from the bitter melon juice can be used for preparing a pharmaceutical formulation embedding a protein, a polypeptide, a small molecule peptide, a nucleic acid, or a small molecule compound. The compositions of the oral medicament of the present invention comprise the bitter melon exosome and an active pharmaceutical ingredient encapsulated in the bitter melon exosome. The bitter melon exosome is suitable for preparing a drug that is easily damaged by the gastrointestinal tract and is mostly administered by means of an injection route into an oral agent, and the oral agent can produce a similar therapeutic effect to that of the injection administration route by oral administration, and is convenient to use. The extraction method for the bitter melon exosome is simple and has a low cost. Moreover, the bitter melon exosome has no immunogenicity, has relatively high biocompatibility and biosafety, and has relatively strong tolerance to gastric acid and digestive tract proteolytic enzymes, and intestinal barrier permeability.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The utility model relates to the technical field of oral medicine rotary notice boards, and discloses a rotary notice board for reminding an elderly patient to advice oral medicine, which comprises a mounting support clamp and an oral medicine advice rotary disc mounted on the mounting support clamp, the mounting support clamp is bent, a plurality of positioning holes are arranged on the oral medicine advice rotary disc, and the positioning holes are communicated with the mounting support clamp. A rotating structure is arranged on the periphery of each positioning hole, each rotating structure comprises a fan-shaped sticker arranged on the surface of an advice and notice support oral medicine rotating disc located over the corresponding positioning hole, and words of'medicine taking 'are written on the fan-shaped stickers. By using the rotary notice board for oral medicine taking in the advice, the on-time medicine taking rate of hospitalized elderly patients is improved, the medicine taking safety of the patients is ensured, the satisfaction degree of the patients and family members is improved, the working safety of nurses is effectively ensured, and adverse effects such as missed medicine taking, repeated medicine taking and the like are avoided.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

The present invention relates to a monolithic tablet composition for oral administration of tofacitinib or a pharmaceutically acceptable salt thereof, without a functional coating.

The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Provided are a heteroaromatic ring compound represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The heteroaromatic ring compound has good inhibitory activity and selectivity on FGFR2 abnormity, and compared with human small cell lung cancer cells DMS114 and human bladder cancer cells RT112 / 84, the heteroaromatic ring compound shows good proliferation inhibitory activity on human gastric cancer cells SNU-16. The heteroaromatic ring compound can be well absorbed after oral administration, and has good drug exposure in a rat body.

The present invention relates to compounds comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to pharmaceutical formulations suitable for, but not limited to, oral administration, comprising such compounds. The compounds and pharmaceutical formulations comprising the same are useful in the medical treatment of subjects suffering from overweight, obesity and associated co-diseases.